Alzamend Neuro Overview
- Founded
- 2016
- Status
- Private
- Employees
- 4
- Latest Deal Type
- Angel
- Latest Deal Amount
- $232K
Alzamend Neuro General Information
Description
Developer of immunotherapeutic treatment and vaccines designed to treat Alzheimer's diseases. The company has developed mutant-peptide immunotherapeutic (AL002) for use as a treatment or vaccine and a lithium-based ionic cocrystal therapy (AL001) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with Alzheimer, enabling patients to recover from Alzheimer's diseases.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 201 Shipyard Way Suite E
- Newport Beach, CA 92663
- United States
+1 (844) 000-0000
Alzamend Neuro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Angel (individual) | 19-Apr-2019 | $232K | 00.000 | Completed | Startup | |
| 2. Angel (individual) | 22-Aug-2017 | 000 | Cancelled | Startup | ||
| 1. Angel (individual) | 01-Jul-2016 | $1M | $1M | Completed | Startup |
Alzamend Neuro Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Stephan Jackman | Chief Executive Officer | ||
| Kenneth Cragun | Chief Financial Officer & Treasurer | ||
| Milton Ault III | Founder & Chairman |
Alzamend Neuro Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Milton Ault III | Self | Founder & Chairman | 000 0000 |
| Philip Mansour | Alzamend Neuro | Board Member | 000 0000 |
| William Horne | Alzamend Neuro | Board Member | 000 0000 |
Alzamend Neuro Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial